Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27197786 | 0.94 | ACKR3 (0.47) | ACKR3ACHEGPR119TBK1POLB | |
| SCHEMBL1742604 | 0.87 | ACKR3 (0.51) | ACKR3SIGMAR1TLR8ADORA3HTR2A | |
| SCHEMBL24541956 | 0.83 | ACKR3 (0.46) | ACKR3ACHEGPR119TBK1POLB | |
| SCHEMBL7971782 | 0.81 | SIGMAR1 (0.69) | ACKR3SIGMAR1ADORA3HTR2AHTR7 | |
| SCHEMBL31752794 | 0.80 | SIGMAR1 (0.56) | ACKR3SIGMAR1TLR8ADORA3HTR2A | |
| SCHEMBL1742612 | 0.78 | ACKR3 (0.49) | ACKR3SIGMAR1TLR8ADORA3HTR2A | |
| SCHEMBL30812306 | 0.78 | SIGMAR1 (0.54) | ACKR3SIGMAR1ADORA3HTR2AHTR7 | |
| SCHEMBL27980806 | 0.78 | SIGMAR1 (0.54) | ACKR3SIGMAR1ADORA3HTR2AHTR7 | |
| SCHEMBL24541948 | 0.77 | GPR119 (0.44) | ACKR3SIGMAR1ACHEGPR119TBK1 | |
| SCHEMBL1744477 | 0.77 | SIGMAR1 (0.50) | ACKR3SIGMAR1GPR119TLR8ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426113-B1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | KOWA CO (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2426113-A1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | Kowa Company, Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | ACKR3 39/4885SIGMAR1 1187/4885ACHE 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.